Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Iniciando a tecnologia no estudo sobre diabetes tipo 1 em risco (STAR-T1D)

26 de outubro de 2026 atualizado por: Estelle M. Everett, MD, MHS, University of California, Los Angeles

Iniciando a tecnologia no estudo de diabetes tipo 1 em risco (STAR-T1D)

Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.

Visão geral do estudo

Status

Recrutamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • California
      • Santa Monica, California, Estados Unidos, 90404
      • Sylmar, California, Estados Unidos, 91342
        • Recrutamento
        • Olive View-UCLA Medical Center
        • Contato:
      • Torrance, California, Estados Unidos, 90502
        • Recrutamento
        • Harbor-UCLA Medical Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Type 1 Diabetes
  • A1c ≥ 8.0%
  • Not insulin pump user
  • Primary language of English or Spanish
  • Have medical insurance coverage

Exclusion Criteria:

  • No measured A1c in the past year
  • Have comorbidities that can result in inaccurate hemoglobin A1c
  • Have cognitive, physical or mental impairment precluding diabetes technology use
  • Limited life expectancy (<1 year)
  • Pregnancy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Hybrid Closed Loop Insulin Pump System

Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions.

Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks.

Patients will be started on an automated insulin delivery system.

Sem intervenção: Control

Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions.

Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of screened participants that are eligible
Prazo: 6 months

Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data.

6 months
Proportion of enrolled participants that are randomized
Prazo: 6 months

Randomized among enrolled, and receiving allocated intervention among randomized.

6 months
Proportion of average time delay to enrollment
Prazo: 6 months

Average time delay from screening to enrollment.

6 months
Proportion of retention among participants randomized to the Intervention Group
Prazo: 6 months

Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized.

6 months
Proportion of retention among participants randomized
Prazo: 6 months

Participants lost to follow-up among those initially randomized.

6 months
Proportion of retention among participants randomized
Prazo: 6 months

Retention rates by participants completing all research assessments among randomized.

6 months
Number of participants who adhere to assigned treatment
Prazo: 6 months

Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed.

Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate.

Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate.

6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in A1c
Prazo: 6 months

Serum Hemoglobin A1c laboratory measurement

6 months
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
Prazo: 6 months

Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl.

6 months
Mean Diabetes Ketoacidosis Episodes Incidence
Prazo: 6 months

Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews.

6 months
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
Prazo: 6 months

Number of diabetes related ED visits or hospitalizations

6 months
Treatment Burden and Satisfaction: Diabetes Distress
Prazo: 6 months

Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5.

6 months
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
Prazo: 6 months

Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life.

6 months
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
Prazo: 6 months

Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each.

6 months
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
Prazo: 6 months

Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome.

WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9.

6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

5 de setembro de 2024

Conclusão Primária (Estimado)

31 de janeiro de 2027

Conclusão do estudo (Estimado)

1 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

26 de abril de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de junho de 2024

Primeira postagem (Real)

12 de junho de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

29 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de outubro de 2026

Última verificação

1 de novembro de 2025

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever